Jane Street’s NeuroSense Therapeutics NRSN Stock Holding History

Jane Street’s Portfolio NRSN Stock Details NRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$21.6K	Buy	+28,670	New	+$25.6K	﹤0.01%	11184
2025 Q3	–	Sell	-28,689	Closed	-$54.2K	–	11455
2025 Q2	$54.2K	Buy	+28,689	New	+$41.6K	﹤0.01%	9150
2025 Q1	–	Sell	-64,636	Closed	-$77.6K	–	10243
2024 Q4	$77.6K	Buy	+64,636	New	+$74.3K	﹤0.01%	8857
2022 Q3	–	Sell	-77,249	Closed	-$261K	–	10199
2022 Q2	$261K	Buy	77,249 +33,751	+78%	+$64K	﹤0.01%	7821
2022 Q1	$173K	Buy	+43,498	New	+$104K	﹤0.01%	9128

Other funds holding NRSN

YAG

Yorkville Advisors Global Mountainside, New Jersey $155M AUM 58.46% 1-Year Est. Return

IAA

Independent Advisor Alliance Charlotte, North Carolina $9.32B AUM 33.19% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Jane Street's NRSN Position: Q1 2026 in Review

Jane Street opened a new position in NeuroSense Therapeutics (NRSN) in Q1 2026: 28,670 shares worth $21.6K. The stake represents ﹤0.01% of the portfolio and ranks #11184 among its holdings. This is a return to the name: Jane Street previously reported a position in NRSN as recently as Q2 2025.

Jane Street first reported a position in NRSN in Q1 2022 and has held it in 5 quarters since. The position peaked at $261K in Q2 2022. 13 funds tracked by Wall St. Rank hold NRSN as of Q1 2026.

Jane Street held 28,670 shares of NeuroSense Therapeutics worth $21.6K as of Q1 2026.
NeuroSense Therapeutics was a new Jane Street position in Q1 2026.
NeuroSense Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #11184 holding.
Jane Street first reported a position in NeuroSense Therapeutics in Q1 2022 and has held it in 5 quarters since.
Jane Street's NeuroSense Therapeutics position peaked at $261K in Q2 2022.
13 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.